Tab%25252520voihep

# Tabvoihep (Tenofovir Alafenamide/Emtricitabine) ## Overview Tabvoihep is a co-formulated fixed-dose combination tablet containing Tenofovir Alafenamide (TAF) and Emtricitabine (FTC). It is a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) combination used in the treatment of HIV-1 infection. ## Primary Indications Treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg. ## Adult Dosing Standard dose is one tablet (25 mg TAF / 200 mg FTC) once daily, taken orally with or without food. ## Pediatric Dosing Patients must weigh at least 14 kg. Dosing depends on weight-based tablet combinations when using individual components; if using a co-formulated generic, follow weight-band specific labeling. * **14 kg to < 25 kg:** Follow local protocol/product labeling for specific pediatric strength. * **≥ 25 kg:** One tablet (25 mg TAF / 200 mg FTC) once daily. ## Dose Adjustments * **Renal Impairment:** Not recommended in patients with estimated creatinine clearance (CrCl) < 30 mL/min (or < 15 mL/min if receiving chronic hemodialysis). * **Hepatic Impairment:** No dose adjustment required for mild (Child-Pugh A) hepatic impairment. Avoid use in patients with severe (Child-Pugh C) hepatic impairment. ## Contraindications No specific contraindications identified other than hypersensitivity to any component of the formulation. ## Adverse Effects * **Common:** Nausea, abdominal pain, fatigue, headache, dizziness, insomnia, cough, and rash. * **Serious:** Lactic acidosis/severe hepatomegaly with steatosis, acute exacerbation of Hepatitis B (if co-infected), and potential for decreased bone mineral density or proximal renal tubulopathy (though risk is lower than with Tenofovir Disoproxil Fumarate). ## Key Drug Interactions * **P-gp/BCRP Inducers:** Concomitant use with strong inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) may significantly decrease TAF concentrations and is generally not recommended. * **Nephrotoxic Agents:** Avoid concurrent use with medications that cause renal impairment (e.g., NSAIDs, aminoglycosides) as this may increase the risk of tenofovir-related toxicity. ## Monitoring * **Baseline/Ongoing:** CrCl, urine glucose and protein (in patients with renal risk), and lipid profile. * **Hepatitis B:** Screen all patients for HBV status; monitor for exacerbations if therapy is discontinued in co-infected patients. ## Clinical Pearls * TAF has a higher intracellular concentration in peripheral blood mononuclear cells but lower plasma concentration compared to Tenofovir Disoproxil Fumarate (TDF), resulting in improved renal and bone safety profiles. * If a dose is missed, take it as soon as possible, provided it is not time for the next scheduled dose. Do not double doses. * Always confirm specific generic labeling if sourcing "Tabvoihep," as regional labeling may vary significantly compared to reference Raltegravir/TAF/FTC combinations. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical guidelines and prescribing information change frequently. Always consult the most current manufacturer prescribing information, institutional protocols, and official clinical guidelines (e.g., DHHS or WHO HIV treatment guidelines) before initiating or adjusting therapy.